Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of a fixed dose combination (FDC) of
glecaprevir/pibrentasvir (G/P) given for 4 weeks in acute hepatitis C (HCV)-infected
participants, with or without HIV-1 coinfection.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
AbbVie National Institute of Allergy and Infectious Diseases (NIAID)